Lessons From Antagonizing the Cellular Effect of Thrombin–Coronary Artery Disease - LANCELOT–CAD

Description:

Atopaxar is a novel protease-activated receptor-1 (PAR-1) antagonist (formerly known as E5555) that has shown promising results in early clinical studies. LANCELOT−CAD was a phase II trial designed to study the safety and efficacy of atopaxar in patients with chronic coronary artery disease (CAD).